Ritholtz Wealth Management Krystal Biotech, Inc. Transaction History

Ritholtz Wealth Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$62.14 - $81.82 $217,490 - $286,370	-3,500 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$59.42 - $85.46 $207,970 - $299,110	3,500 New	3,500 $270,000
Q4 2020 Jan 19, 2021	SELL	$40.64 - $61.38 $284,480 - $429,660	-7,000 Closed	0 $0
Q3 2020 Oct 23, 2020	SELL	$37.76 - $48.49 $120,832 - $155,168	-3,200 Reduced 31.37%	7,000 $301,000
Q2 2020 Jul 15, 2020	BUY	$37.03 - $60.0 $44,436 - $72,000	1,200 Added 13.33%	10,200 $422,000
Q1 2020 Apr 09, 2020	BUY	$35.02 - $65.64 $35,020 - $65,640	1,000 Added 12.5%	9,000 $389,000
Q3 2019 Oct 17, 2019	SELL	$34.72 - $51.3 $396,120 - $585,281	-11,409 Reduced 58.78%	8,000 $278,000
Q1 2019 Apr 12, 2019	BUY	$19.86 - $32.9 $99,300 - $164,500	5,000 Added 34.7%	19,409 $639,000
Q4 2018 Jan 18, 2019	BUY	$15.03 - $25.38 $216,567 - $365,700	14,409 New	14,409 $299,000

266

25M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.66B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Ritholtz Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Ritholtz Wealth Management with notifications on news.